Drug · DIN 02431955
RIXUBIS
SINGLE-USE VIAL AND DILUENT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 22, 2021; first marketed April 18, 2017.
- Drug Identification Number (DIN)
- 02431955
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Powder For Solution; Kit
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor ix B02BD04
- Class
- Human
- Record last updated
- July 30, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| NONACOG GAMMA | 2000 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 12, 2021: NOC 25438New Drug Submission (NDS) · Transfer of drug identification number. labelling updates
- April 13, 2018: NOC 20747New Drug Submission (NDS)
- April 21, 2015: NOC 16817New Drug Submission (NDS) · Manufacturer name change
- September 30, 2014: NOC 16142New Drug Submission (NDS)
Other DINs named RIXUBIS
- DIN 02431947 · Marketed
- DIN 02431963 · Marketed
- DIN 02431920 · Dormant
- DIN 02431939 · Dormant